CLRB Cellectar Biosciences Inc

Price (delayed)

$2.75

Market cap

$21.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.66

Enterprise value

$15.16M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. ...

Highlights
The company's EPS has surged by 59% YoY and by 20% QoQ
Cellectar Biosciences's net income has increased by 15% YoY and by 4.4% QoQ
The equity has plunged by 61% from the previous quarter and by 60% YoY
CLRB's quick ratio is down by 38% from the previous quarter and by 26% YoY

Key stats

What are the main financial stats of CLRB

CLRB stock price

How has the Cellectar Biosciences stock price performed over time
Intraday
5.77%
1 week
-12.42%
1 month
-2.83%
1 year
-80.14%
YTD
-6.78%
QTD
8.27%

Financial performance

How have Cellectar Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.37M
Net income
-$20.84M
Gross margin
N/A
Net margin
N/A
Cellectar Biosciences's operating income has soared by 52% YoY and by 2.6% from the previous quarter
Cellectar Biosciences's net income has increased by 15% YoY and by 4.4% QoQ

Price vs fundamentals

How does CLRB's price correlate with its fundamentals

Growth

What is Cellectar Biosciences's growth rate over time

Valuation

What is Cellectar Biosciences stock price valuation
P/E
N/A
P/B
3.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 59% YoY and by 20% QoQ
The equity has plunged by 61% from the previous quarter and by 60% YoY
The price to book (P/B) is 50% higher than the last 4 quarters average of 2.2 and 23% higher than the 5-year quarterly average of 2.7

Efficiency

How efficient is Cellectar Biosciences business performance
The company's return on assets has shrunk by 69% YoY and by 4.3% QoQ
The company's return on equity has shrunk by 64% YoY and by 14% QoQ

Dividends

What is CLRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLRB.

Financial health

How did Cellectar Biosciences financials performed over time
The total assets is 74% more than the total liabilities
CLRB's quick ratio is down by 38% from the previous quarter and by 26% YoY
Cellectar Biosciences's current ratio has decreased by 36% from the previous quarter and by 23% YoY
The company's debt is 54% lower than its equity
The equity has plunged by 61% from the previous quarter and by 60% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.